Market Overview

Morgan Stanley Sees Possible Good Things Ahead For Medtronic

Share:
Related MDT
Earnings Scheduled For February 21, 2017
DexCom Jumps 25% As It Becomes Only Continuous Glucose Monitoring With Medicare Coverage
Is Trump About To Blow Up Medtronic's Tax Avoidance Business Model? (Seeking Alpha)

In a report published Friday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Medtronic (NYSE: MDT).

In the report, Morgan Stanley noted, “Reveal Linq may the sleeper product of HRS 2014. First generation Reveal was a tertiary product worth only ~$50-60 million in sales, but the second gen device is different. Reveal Linq makes major strides in innovation and telemetry and comes at a 20% price premium. With unusually strong clinical feedback, this device could open up a renewed global market for cardiac monitoring worth $500 million or more.”

Medtronic closed on Thursday at $59.43.

Latest Ratings for MDT

DateFirmActionFromTo
Jan 2017JP MorganDowngradesOverweightNeutral
Jan 2017Morgan StanleyDowngradesOverweightEqual-Weight
Nov 2016OppenheimerMaintainsOutperform

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (MDT)

View Comments and Join the Discussion!